Stifel Upgrades Supernus Pharmaceuticals (SUPN) to Buy, Would be Buyer On Weakness

November 8, 2017 4:30 AM

Stifel upgraded Supernus Pharmaceuticals (NASDAQ: SUPN) from Hold to Buy with a price target of $47.00.Analyst Annabel Samimy believes with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found